Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalent, Inc (CTLT) CEO John Chiminski on Q2 2020 Results - Earnings Call Transcript

Catalent Inc (NYSE: CTLT), a contract development and manufacturing organization, or CDMO, that provides services for the development of drugs, biologics, gene therapies and consumer health products, said Monday it has agreed to buy MasTherCell Global for $315 million in cash.

Catalent To Buy Cell Therapy CDMO MasTherCell For $315M

Catalent (CTLT) delivered earnings and revenue surprises of 0.00% and 3.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Matches Q2 Earnings Estimates

Drug manufacturer Catalent is ready to capitalize on the drug industry's shifting norms.

Insurers Take Aim at Big Pharma. This Small-Cap Stock Stands to Win.

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Reports Next Week: What You Should Expect

Repligen

These companies aren't household names, but they quietly enable customers across the pharmaceutical and biopharmaceutical sectors to bring innovative new products to market.

2 Stocks to  Buy and Hold for Decades

BridgeBio Pharma Inc

PALO ALTO, Calif., Jan.  10, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration agreement with Catalent to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy clinical and commercial manufacturing center in Harmans, Maryland. The agreement is intended to support the clinical and commercial manufacturing needs for BridgeBio’s gene therapy product candidates for congenital adrenal hyperplasia, BBP-631, and Canavan disease, BBP-812.

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

Catalent, Inc (CTLT) CEO John Chiminski on Q1 2020 Results - Earnings Call Transcript

Catalent (CTLT) delivered earnings and revenue surprises of 8.33% and 4.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Surpasses Q1 Earnings and Revenue Estimates

Allergan

Jazz Pharmaceuticals

Mylan

Regeneron Pharmaceuticals

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

Neurocrine Biosciences

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

CTLT or NBIX: Which Is the Better Value Stock Right Now?

Tandem Diabetes Care

These two healthcare businesses are capturing formidable growth opportunities by executing in their overlooked niches.

2 Growth Stocks for In-the-Know Investors.

It's not a household name, but has made a splash in tackling the biggest pain point in gene therapy: manufacturing.

This Company Is Looking to Win Big in Gene Therapy

Catalent (CTLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Catalent (CTLT) Upgraded to Buy: Here's Why

KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end.

Catalent Analyst Cites Valuation Concerns In Downgrade

Catalent, Inc. (CTLT) CEO John Chiminski on Q4 2019 Results - Earnings Call Transcript

Catalent (CTLT) delivered earnings and revenue surprises of 9.38% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Surpasses Q4 Earnings and Revenue Estimates

Catalent earnings rose modestly to 70 cents a share, defying views for a decline to 64 cents. Catalent stock earns highs scores by IBD metrics.

Catalent Earnings Unexpectedly Rise

Catalent (NYSE: CTLT) reported fourth-quarter earnings of 70 cents per share, which beat the analyst consensus estimate of 64 cents by 9.37%.

Catalent Reports Q4 Earnings Beat

On Tuesday, August 27, Catalent (NYSE: CTLT) will release its latest earnings report.

Catalent's Q4 Earnings Outlook

Earnings Preview: Catalent (CTLT) Q4 Earnings Expected to Decline

Arrow Electronics

Bunge Global SA

Brooks Automation

Exelixis

F.N.B. Corp.

Graphic Packaging Hld

Qorvo

Teladoc

XPO Logistics

Qorvo, Catalent and XPO Logistics are just some of the up-and-coming stocks too many investors are still overlooking.

10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar

Zoetis

CTLT vs. ZTS: Which Stock Is the Better Value Option?

News for Catalent Stock (CTLT)